Carbapenem-resistant Enterobacteriaceae at a low prevalence tertiary care center: Patient-level risk factors and implications for an infection prevention strategy

Michelle Doll; Nadia Masroor; Yvette Major; Michele Fleming; Christopher Doern; Kaila Cooper; Michael Stevens; Gonzalo Bearman

doi:10.1016/j.ajic.2017.04.013

Carbapenem-resistant Enterobacteriaceae at a low prevalence tertiary care center: Patient-level risk factors and implications for an infection prevention strategy

Am J Infect Control. 2017 Nov 1;45(11):1286-1288. doi: 10.1016/j.ajic.2017.04.013. Epub 2017 May 29.

Authors

Michelle Doll¹, Nadia Masroor², Yvette Major¹, Michele Fleming¹, Christopher Doern¹, Kaila Cooper¹, Michael Stevens¹, Gonzalo Bearman¹

Affiliations

¹ Virginia Commonwealth University Medical Center, Richmond, VA.
² Virginia Commonwealth University Medical Center, Richmond, VA. Electronic address: [email protected].

PMID: 28571982
DOI: 10.1016/j.ajic.2017.04.013

Abstract

Limited treatment options and a growing global threat from carbapenem-resistant Enterobacteriaceae (CRE) infections illustrate the importance of understanding the epidemiology of CRE. Using a retrospective chart review and point prevalence testing demonstrated specific patient risk factors for CRE-positive clinical cultures in a tertiary medical center with a low CRE prevalence.

Keywords: Carbapenem-resistant Enterobacteriaceae; Intensive care unit; Patient risk factors; Transmission.

MeSH terms

Carbapenem-Resistant Enterobacteriaceae*
Cross Infection / epidemiology*
Cross Infection / etiology
Cross Infection / prevention & control
Enterobacteriaceae Infections / epidemiology*
Enterobacteriaceae Infections / etiology
Enterobacteriaceae Infections / prevention & control
Humans
Prevalence
Risk Factors
Tertiary Care Centers / statistics & numerical data*